GSK · NYSE · STOCK
GSK (GSK) Stock Analysis
$46.51
52W $42.85 – $61.70
51/100
$93.16B
14.6
0.28
Is GSK Bullish or Bearish?
Mixed.
Innellis AI committee rates GSK plc (GSK) Watch with a composite score of 51/100
, based on 6 analysts with 33% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +9.38 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -10.62 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- ROE of 28.3% shows genuine earnings power backing the valuation — Value
- Dividend yield of 3.9% pays you to wait — Value
- EPS growing 42.3% YoY — Growth
- 4 consecutive earnings beats -- consistent execution — Growth
Bear Case
- Price-to-book of 4.5x prices in significant intangible value — Value
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- Price structure making lower highs and lower lows — Technical
- RSI at 27 is in oversold territory (could mean either capitulation or a bounce setup) — Technical
- MACD histogram negative -- bearish momentum — Technical
- Trend and market structure agree -- coherent bearish picture — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
51/100
Agreement
33%
Analysts
6
Conviction
Contested
Sector Rank
Top 91%
of 192 Healthcare peers
Value Analyst
neutral
55
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 28.3% shows genuine earnings power backing the valuation
− Price-to-book of 4.5x prices in significant intangible value
Growth Analyst
bullish
60
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ EPS growing 42.3% YoY
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
bearish
31
/ 100 · High confidence
Price action is deteriorating -- trend and/or momentum are working against this name
− Price structure making lower highs and lower lows
Risk Analyst
bearish
35
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Current ratio of 0.82 is tight -- limited short-term liquidity cushion
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
58
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 50.2 to 50.6.
- New bearish signals: 1 appeared.
- Bearish pressure eased: 1 signal(s) disappeared.
Analyst-level changes:
- Technical Analyst: +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
27.3
Oversold
MACD Histogram
-0.235
Bearish Momentum
Trend Direction
Downtrend
Weekly: Uptrend
Market Structure
Lh Ll
Support
$35.47
Resistance
$55.78
Bollinger %B
0.15
Inside Bands
Price vs Moving Averages
EMA 9
$47.27
Below
EMA 21
$48.35
Below
EMA 50
$49.62
Below
EMA 200
$50.21
Below
Fundamental Analysis
Valuation
87
Growth
66
Profitability
92
Financial Health
37
Cash Flow
70
Valuation
P/E Ratio
14.6×
P/B Ratio
3.98×
PEG Ratio
0.34
Dividend Yield
3.89%
52W High
$61.70
52W Low
$42.85
Quality & Growth
ROE
3496.4%
ROA
936.9%
Gross Margin
7328.6%
Operating Margin
2411.5%
Revenue Growth YoY
—
Debt / Equity
1.03
AI Fundamental Assessment
P/E ratio of 14.6 (inexpensive relative to a 15-40x range); Price-to-book of 4.0x; PEG ratio of 0.3 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 35.0%; Return on assets of 9.4%; Net margin of 14.5%; Gross margin of 73.3%; Current ratio of 0.82 (tight short-term liquidity); Debt-to-equity of 1.03; Free cash flow per share is positive (2.87); Most recent quarter beat estimates by 6.7%; 4 consecutive earnings beats; EPS growth decelerating (+82.4% -> +8.6% QoQ); Analyst estimates rising over recent quarters
Get the Full GSK Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →